ARGX
Price
$706.64
Change
-$5.56 (-0.78%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
42.95B
58 days until earnings call
MTVA
Price
$0.65
Change
+$0.02 (+3.17%)
Updated
Sep 2, 03:02 PM (EDT)
Capitalization
15.35M
Interact to see
Advertisement

ARGX vs MTVA

Header iconARGX vs MTVA Comparison
Open Charts ARGX vs MTVABanner chart's image
argenx SE
Price$706.64
Change-$5.56 (-0.78%)
Volume$2.93K
Capitalization42.95B
MetaVia
Price$0.65
Change+$0.02 (+3.17%)
Volume$1.96K
Capitalization15.35M
ARGX vs MTVA Comparison Chart in %
Loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MTVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGX vs. MTVA commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Buy and MTVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ARGX: $712.20 vs. MTVA: $0.63)
Brand notoriety: ARGX and MTVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 81% vs. MTVA: 16%
Market capitalization -- ARGX: $42.95B vs. MTVA: $15.35M
ARGX [@Biotechnology] is valued at $42.95B. MTVA’s [@Biotechnology] market capitalization is $15.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileMTVA’s FA Score has 0 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • MTVA’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGX is a better buy in the long-term than MTVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 5 TA indicator(s) are bullish while MTVA’s TA Score has 3 bullish TA indicator(s).

  • ARGX’s TA Score: 5 bullish, 4 bearish.
  • MTVA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ARGX is a better buy in the short-term than MTVA.

Price Growth

ARGX (@Biotechnology) experienced а +7.91% price change this week, while MTVA (@Biotechnology) price change was -2.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

ARGX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($43B) has a higher market cap than MTVA($15.3M). ARGX YTD gains are higher at: 15.805 vs. MTVA (-68.759). ARGX has higher annual earnings (EBITDA): 690M vs. MTVA (-20.01M). ARGX has more cash in the bank: 3.93B vs. MTVA (17.6M). MTVA has less debt than ARGX: MTVA (98K) vs ARGX (43.2M). ARGX has higher revenues than MTVA: ARGX (3.05B) vs MTVA (0).
ARGXMTVAARGX / MTVA
Capitalization43B15.3M281,046%
EBITDA690M-20.01M-3,448%
Gain YTD15.805-68.759-23%
P/E Ratio36.24N/A-
Revenue3.05B0-
Total Cash3.93B17.6M22,318%
Total Debt43.2M98K44,082%
FUNDAMENTALS RATINGS
ARGX vs MTVA: Fundamental Ratings
ARGX
MTVA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
17100
SMR RATING
1..100
3899
PRICE GROWTH RATING
1..100
4265
P/E GROWTH RATING
1..100
8356
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MTVA's Valuation (45) in the null industry is in the same range as ARGX (74) in the Pharmaceuticals Other industry. This means that MTVA’s stock grew similarly to ARGX’s over the last 12 months.

ARGX's Profit vs Risk Rating (17) in the Pharmaceuticals Other industry is significantly better than the same rating for MTVA (100) in the null industry. This means that ARGX’s stock grew significantly faster than MTVA’s over the last 12 months.

ARGX's SMR Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for MTVA (99) in the null industry. This means that ARGX’s stock grew somewhat faster than MTVA’s over the last 12 months.

ARGX's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as MTVA (65) in the null industry. This means that ARGX’s stock grew similarly to MTVA’s over the last 12 months.

MTVA's P/E Growth Rating (56) in the null industry is in the same range as ARGX (83) in the Pharmaceuticals Other industry. This means that MTVA’s stock grew similarly to ARGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXMTVA
RSI
ODDS (%)
Bearish Trend 5 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
67%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
69%
Bearish Trend 5 days ago
90%
MACD
ODDS (%)
Bullish Trend 5 days ago
66%
Bullish Trend 5 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
68%
Bearish Trend 5 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
64%
Bullish Trend 5 days ago
77%
Advances
ODDS (%)
Bullish Trend 8 days ago
69%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
62%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
71%
Bullish Trend 6 days ago
90%
Aroon
ODDS (%)
Bullish Trend 5 days ago
63%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MTVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NANR62.190.57
+0.93%
SPDR S&P® North American Natural Res ETF
EPU53.800.38
+0.71%
iShares MSCI Peru ETF
AUGM33.35-0.02
-0.07%
FT Vest U.S. Eq Max Buffr ETF - Aug
SPXV70.80-0.62
-0.86%
ProShares S&P 500® ex-Health Care
VPL86.02-0.86
-0.99%
Vanguard FTSE Pacific ETF

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ALNY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
+1.15%
ALNY - ARGX
50%
Loosely correlated
-1.29%
MTVA - ARGX
43%
Loosely correlated
-1.98%
IONS - ARGX
40%
Loosely correlated
+0.04%
ROIV - ARGX
40%
Loosely correlated
-0.08%
APLS - ARGX
37%
Loosely correlated
-1.71%
More

MTVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MTVA has been loosely correlated with LQDA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MTVA jumps, then LQDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MTVA
1D Price
Change %
MTVA100%
-1.98%
LQDA - MTVA
44%
Loosely correlated
+0.80%
ARGX - MTVA
43%
Loosely correlated
+1.15%
MCRB - MTVA
33%
Poorly correlated
-0.26%
NERV - MTVA
30%
Poorly correlated
-0.84%
KPRX - MTVA
29%
Poorly correlated
N/A
More